Loading…
Loading…
BIIB · NASDAQ · Healthcare
“At twenty times earnings, this biotech reminds me that in pharmaceuticals, yesterday's miracle drug often becomes tomorrow's patent cliff casualty.”
— In the voice of Munger
Evaluate financial health using Piotroski F-Score criteria — profitability, leverage, and operating efficiency metrics.
Market Cap
$26.75B
P/E Ratio
20.69
Forward P/E
—
EPS
$8.83
PEG Ratio
-0.18
Book Value
$124.62
Dividend Yield
—
Profit Margin
13.07%
ROE
7.08%
Use the interactive quality score with pre-loaded data for Biogen Inc. Adjust discount rates, growth assumptions, and projection horizons to model different scenarios.
Pre-loaded inputs for BIIB: